

ASX ANNOUNCEMENT  
25<sup>th</sup> January 2023



## INVESTOR WEBINAR – TUESDAY 31 JANUARY

PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”), developer of the world’s first smart phone-based pain assessment and monitoring application, is pleased to announce it will hold an investor webinar & Q&A for all shareholders and interested parties at 10:00am AEDT on Tuesday 31 January 2023. Managing Director and CEO Philip Daffas will discuss recent business updates including details in the upcoming Quarterly Activity Report.

Please register for the webinar at: [https://us02web.zoom.us/webinar/register/WN\\_iHDXWo6BQw21ciGzLHBhpA](https://us02web.zoom.us/webinar/register/WN_iHDXWo6BQw21ciGzLHBhpA)

After registering, you will receive a confirmation email containing information about joining the webinar as well as dial-in details for those that would prefer to join by phone.

For the Q&A session, investors are invited to send questions prior to the webinar to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au).

Please note a replay of the webinar will be available at the above-mentioned Zoom link shortly following the conclusion of the live session.

This release has been authorised for release by PainChek CEO Philip Daffas.

### For more information:

Lisa Dadswell  
Company Secretary, PainChek  
[lisa.dadswell@boardroomlimited.com.au](mailto:lisa.dadswell@boardroomlimited.com.au)  
02 8016 2819

Philip Daffas  
CEO, PainChek  
[philip.daffas@painchek.com](mailto:philip.daffas@painchek.com)  
0406 537 235

### About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

Pain often goes unrecognised and under-treated in people with communication difficulties. PainChek Universal is a clinically validated smartphone-based medical device that enables best practice pain assessment for all people, everywhere.

PainChek Universal is a complete point-of-care solution that combines the existing PainChek® App with the Numerical Rating Scale (NRS). This enables best-practice pain management for all residents living with pain in any environment — from those who cannot verbalise pain to those who can, and those who fluctuate between the two.

The PainChek® App uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalise pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the Numerical Rating Scale, a well-established standard used to document pain levels amongst these individuals. PainChek Universal also

supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for infants who have not yet learnt to speak. Both the adult and infants products have received regulatory clearance in numerous markets including Australia, Europe, UK, NZ, Singapore and Canada.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit [www.painchek.com](http://www.painchek.com)